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Tankyrase-1 multimerizes via its sterile alpha motif domain, but its functional implication remains
elusive. Here, we found that excessive amounts of tankyrase-1 form punctate nuclear foci. This focus
formation depends on both homophilic multimerization and heterophilic protein–protein interac-
tion. These foci are functionally dormant because they do not efﬁciently release TRF1 from telo-
meres. Consistently, hyper-overexpression of tankyrase-1 attenuates its ability to elongate
telomeres. These observations suggest that tankyrase-1 assembly to large protein complexes masks
its telomeric function.
Structured summary:
MINT-7987689, MINT-7987677: Tankyrase-1 (uniprotkb:O95271) and TRF1 (uniprotkb:P54274)
colocalize (MI:0403) by ﬂuorescence microscopy (MI:0416)
MINT-7987977: Tankyrase-1 (uniprotkb:O95271) physically interacts (MI:0915) with TRF1 (uni-
protkb:P54274) by anti tag coimmunoprecipitation (MI:0007)
MINT-7987998: Tankyrase-1 (uniprotkb:O95271) physically interacts (MI:0915) with Tankyrase-1 (uni-
protkb:O95271) by anti tag coimmunoprecipitation (MI:0007).
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction [7,8]. Actually, tankyrase-1 forms large protein complexesTankyrase-1 poly(ADP-ribosyl)ates (PARsylates) a telomeric re-
peat-binding factor 1 (TRF1) [1]. PARsylated TRF1 dissociates from
telomeres, resulting in an ‘‘open” state of telomeres. Thus, tankyr-
ase-1 overexpression in human cells enhances telomere access of
telomerase, which in turn elongates telomeres [2]. Since unusual
maintenance of telomere length against the DNA end replication
problem is an essential factor for cancer cell immortality, tankyr-
ase-1 has been postulated as a target for cancer therapy [3,4].
Tankyrase-1 has ﬁve domains called ankyrin repeat cluster
(ARC) I to V (see Fig. 3A), each of which works as an independent
TRF1-binding unit [5,6]. Among them, ARC V is essential for TRF1
PARsylation [6]. Meanwhile, tankyrase-1 has a sterile alpha motif
(SAM) domain, which contributes to protein multimerizationchemical Societies. Published by E
yrin repeat cluster; FN, FLAG
eacetylase; PARP, poly(ADP-
ion; SAM, sterile alpha motif;
atin A; VPA, valproic acid(>2000 kDa) via the SAM domain both in vitro and in intact cells.
In the cytoplasm, tankyrase-1 multimerization seems to be re-
quired for further assembly of punctate protein foci and larger ves-
icles, which presumably affect the apical secretion pathway [8].
However, the functional signiﬁcance of tankyrase-1 multimeriza-
tion in telomere length regulation is unknown. Here, we screened
compounds that induce tankyrase-1 multimerization (i.e., nuclear
focus formation), and found that hyper-overexpression of exoge-
nous tankyrase-1 by histone deacetylase (HDAC) inhibitors leads
to its focus formation in SAM- and ARC-dependent manners.
Importantly, these foci were functionally inactive. This study dem-
onstrates a novel regulation mechanism of tankyrase-1, which is
distinct from modulation of the poly(ADP-ribose) polymerase
(PARP) catalytic activity.
2. Materials and methods
2.1. Plasmids
The FLAG-nuclear localization signal (NLS)–tagged tankyrase-1
(FN-tankyrase-1) has been described [2]. Because more than halflsevier B.V. All rights reserved.
3886 K. Hatsugai et al. / FEBS Letters 584 (2010) 3885–3890of endogenous tankyrase-1 resides outside the nucleus, NLS tagging
to the exogenous gene allowed us to enhance the tankyrase-1 func-
tion exclusively in the nucleus [2]. FN-tank-DARC III-V and FN-tank-
PARP-deadwere constructed as described [6,9]. FN-tank-DSAMwas
generated by PCR with pLPC/FN-tankyrase-1 (Fig. 3A).
2.2. Fluorescence microscopy
Immunoﬂuorescence staining was performed as described [10].
In brief, cells were transfected with each vector. After incubation
for 20 h, cells were ﬁxed with 2% paraformaldehyde and permeabi-
lized with 0.5% Nonidet P-40. Cells were stained with anti-FLAG
(M2) and anti-TRF1 (5747) [6]. For immuno-FISH, the permeabili-
zed cells were hybridized with Cy3-PNA (CCCTAA)3 [3] and stained
with anti-FLAG.
2.3. Western blot analysis
Western blot analysis was performed as described [5] with anti-
tankyrase-1 (H-350, Santa Cruz Biotechnology, Santa Cruz, CA),
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (10R-
G109a), or anti-Myc (A-4, Santa Cruz Biotechnology).
2.4. Co-immunoprecipitation
TNE lysates [5] were incubated with anti-FLAG M2 afﬁnity gel
(Sigma-Aldrich, St. Louis, MO) for 1 h. After washing with the PARP
reaction buffer [1], the bead-bound proteins were subjected to
western blot analysis.
2.5. Southern blot analysis
FN-tankyrase-1-overexpressing HTC75 cells (HTC75/FN-tankyr-
ase-1) [6] were treated with 125 nM trichostatin A (TSA) for up toMock
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Tankyrase-1
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Fig. 1. Focus formation of exogenous tankyrase-1 by HDAC inhibitors. (A) Tankyrase-1–m
enhanced green ﬂuorescence protein (EGFP)–FN-tankyrase-1 and incubated with or
nucleoplasmic distribution with the loss of telomeric TRF1 dots whereas 3AB induced tel
HDAC inhibitors. Cells were transfected with EGFP–FN-tankyrase-1 (Exp. 1) or FN-tanky
apicidin, 5 mM VPA, 5 lM MS-275, 0.5 lM HC-toxin, or 0.5 lM CHAHA for 18 h. These t
were analyzed for each compound. (C) Confocal microscopy conﬁrmed that tankyrase-1130 PD. Telomeric restriction fragments (TRF), which correspond to
telomeric and subtelomeric DNAs, were detected by Southern blot
analysis [6].
3. Results
3.1. HDAC inhibitors induce non-telomeric foci of exogenous
tankyrase-1
Tankyrase-1 overexpression in the nuclei of HeLa I.2.11 cells
eliminates the nuclear TRF1 dots, reﬂecting dissociation of TRF1
from telomeres and degradation of the protein (Fig. 1A, top and
middle) [2,11]. In these cells, the exogenous tankyrase-1 exhibited
ﬂat nucleoplasmic distribution (Fig. 1A, middle). Treatment with 3-
aminobenzamide (3AB, a PARP inhibitor) caused tankyrase-1 foci
by tethering tankyrase-1 to the TRF1 dots (Fig. 1A, bottom) [3].
Thus, tankyrase-1 inhibition can be visualized by its focus
formation.
To examine the mechanism for tankyrase-1 inhibition in intact
cells, we screened the Screening Committee of Anticancer Drugs
(SCADS) inhibitor kit, consisting of 95 function-deﬁned inhibitors
[12], for a compound that induces the tankyrase-1 foci. We found
that HDAC inhibitors, Scriptaid and TSA, induce the foci (Fig. 1B,
Exp. 1). This focus formation was also observed upon treatment
with other structurally related (CHAHA) and unrelated [apicidin,
valproic acid (VPA), MS-275, HC-toxin] HDAC inhibitors (Fig. 1B,
Exp. 2; Supplementary Fig. 1), indicating that this effect was de-
rived from HDAC inhibition. While these inhibitors blocked the
TRF1 release from telomeres, the tankyrase-1 foci did not colocal-
ize with TRF1 or telomeres (Fig. 1C and 2). These results suggest
that HDAC inhibitors block the tankyrase-1 transgene in a different
way than PARP inhibitors.ge
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Fig. 2. Non-telomeric nuclear foci of exogenous tankyrase-1. HeLa I.2.11 cells were transfected with pLPC/FN-tankyrase-1 and incubated with the compounds for 18 h.
Concentrations of the compounds were the same as in Fig. 1B. FN-tankyrase-1 and telomeres were detected by immuno-FISH.
K. Hatsugai et al. / FEBS Letters 584 (2010) 3885–3890 38873.2. HDAC inhibitors cause hyper-overexpression of CMV promoter–
driven tankyrase-1
HDAC inhibitors might enhance tankyrase-1 acetylation, which
in turn could disrupt the protein’s function. However, we did not
detect acetylated tankyrase-1 in HDAC inhibitor–treated cells (data
not shown). HDAC inhibitors enhance gene expression driven by a
CMV promoter [[13]; Okabe, S., Mashima, T., Seimiya, H., unpub-
lished observation] that was used for the expression of the tankyr-
ase-1 constructs in this study. Indeed, VPA and TSA signiﬁcantly
increased the expression of exogenous tankyrase-1 (Fig. 3B, top pa-
nel). This effect was speciﬁc, because it was not the case for 3AB.
VPA and TSA also increased the level of endogenous tankyrase-1,
but it was only marginal (Supplementary Fig. 2), supporting that
HDAC inhibitors cause hyper-overexpression of the exogenous
tankyrase-1.
3.3. Formation of non-telomeric tankyrase-1 foci requires SAM and
ARC domains
Since tankyrase-1 multimerizes in its concentration-dependent
manner [8], an elevated concentration of tankyrase-1 in the nu-
cleus may lead to the self-association. If this were the case, the fo-
cus formation by HDAC inhibitors would be abolished by deletionof SAM domain. Actually, FN-tank-DSAM, which lost the ability to
self-associate (Fig. 3A and C), did not form nuclear foci upon treat-
ment with VPA or TSA (Fig. 4). This mutant retained hyper-overex-
pression upon treatment with the HDAC inhibitors (Fig. 3B). SAM
domain is not sufﬁcient to form large protein complexes in intact
cells [8]. Thus, tankyrase-1 focus formation would need heterophil-
ic protein interaction, in addition to SAM domain–mediated multi-
merization. So, we examined another mutant, FN-tank-DARC III-V,
which lacks the C-terminal portion of ARCs (Fig. 3A and B). This
mutant retained ARC I-II and SAM domains and thus could bind
TRF1 and tankyrase-1, respectively (Fig. 3C). However, since this
mutant lacks the essential ARC V for ligand PARsylation, it cannot
elongate telomeres [6]. This mutant did not form nuclear foci upon
treatment with HDAC inhibitors (Fig. 4). These observations indi-
cate that tankyrase-1 focus formation involves both homophilic
and heterophilic interactions via SAM and ARC domains, respec-
tively. The catalytically inactive mutant FN-tank-PARP-dead
(Fig. 3A) partially lost the ability to form the HDAC inhibitor-in-
duced foci (Fig. 4), indicating that the focus formation occurs in
PARP activity-dependent and -independent manners. SAM and
ARC domains were also required for the focus formation by 3AB
(Fig. 4).
Since HDAC inhibitors would also affect the expression of vari-
ous genes, other proteins induced by HDAC inhibitors might be in-
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same as in Fig. 1B. The cell lysates were subjected to western blot analysis (WB). Numbers indicate the size markers. (C) Cells were transfected with FN-tankyrase-1
constructs and Myc-tankyrase-1 or Myc-TRF1. Cell lysates were subjected to immunoprecipitation (IP), followed by WB.
3888 K. Hatsugai et al. / FEBS Letters 584 (2010) 3885–3890volved in the formation of tankyrase-1 foci. However, transfection
with higher amounts of the plasmid, which elevated the expression
level of the exogenous tankyrase-1, increased the frequency of
spontaneous formation of the non-telomeric tankyrase-1 foci (data
not shown). This result indicates that the excessive expression of
tankyrase-1 causes its self-assembly.Wild-type
PARP
dead ΔSAM ΔARC II
FN-tankyrase-1
3AB
VPA
No drug
A
TSA
Fig. 4. Tankyrase-1 SAM and ARC domains mediate the focus formation. (A) HeLa I.2
counterstained by DAPI (blue). (B) Quantitative graph of the localization patterns of the3.4. Hyper-overexpression of tankyrase-1 attenuates its ability to
elongate telomeres
It is likely that the multimerized tankyrase-1 foci, which did not
eliminate the TRF1 dots in the nucleus, lost the ability to elongate
telomeres. To examine this possibility, we continuously treatedB
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TSA. In these cells, FN-tankyrase-1 is stably overexpressed under
the CMV promoter and further induced by TSA (Fig. 5A). While
mock cells maintained the telomere length, HTC75/FN-tankyrase-
1 cells elongated telomeres (Fig. 5B and C). As expected, TSA pre-
vented efﬁcient telomere elongation. TSA allowed moderate telo-
mere elongation, which was consistent with the observation that
TSA-treated cells exhibited a slight nucleoplasmic distribution of
FN-tankyrase-1 (Figs. 2 and 4). TSA did not shorten telomeres in
mock cells or inhibit telomerase activity in vitro (data not shown),
indicating that HDAC inhibition has no detectable effect on the
endogenous telomere maintenance machinery. We could not
examine the effect of VPA on telomere length because chronic
exposure to VPA was cytotoxic. These observations support that
tankyrase-1 multimerization and subsequent larger protein com-
plex formation block its telomeric function.
4. Discussion
Since tankyrase-1 expression is elevated in several cancers
[14,15], it may play a role in carcinogenesis. This implies that tank-
yrase-1 could be a molecular target for cancer therapy. In fact,
tankyrase-1 inhibition boosts the anticancer impact of a telome-
rase inhibitor [3]. Tankyrase-1 inhibition also induces synthetic
lethality with BRCA-deﬁciency in multiple cancers [16]. Moreover,
identiﬁcation of tankyrases as axin-destabilizing proteins has
opened the door for a therapy against Wnt signaling-dependent
cancers [17].Meanwhile, tankyrase-1-mediated down-regulation of TRF1
suppresses the mitotic abnormalities led by Aurora-A [9]. Namely,
TRF1 mediates Aurora-A-induced occurrence of lagging chromo-
somes, resulting in tetraploidization of a cell [9]. Our present study
suggests that too excessive up-regulation of tankyrase-1 may in-
duce its focus formation and disturb, rather than enhance, TRF1
PARsylation. In that case, TRF1 would remain undegraded and
mediate the Aurora-A-induced tetraploidization. Because tankyr-
ase-1 and Aurora-A are frequently overexpressed in breast cancer
[14,18], it would be interesting to determine the relationship be-
tween the expression levels of those proteins and ploidy altera-
tions in such tumors.
Our ﬁnding that tankyrase-1 could be auto-regulated by form-
ing dormant protein complexes would provide a novel clue for
developing tankyrase inhibitors [17,19]. Thus, compounds that in-
duce multimerization and focus formation of tankyrases may be
utilized as functional inhibitors of the proteins. Such compounds
would not affect PARsylation catalyzed by other PARPs and might
be expected to exhibit a highly selective effect.
Acknowledgments
We thank Satoshi Tokunaga for assistance on Southern hybrid-
ization, laboratory members for discussion, and Screening Com-
mittee of Anticancer Drugs supported by Grant-in-Aid for
Scientiﬁc Research on Priority Area ‘‘Cancer” from The Ministry
of Education, Culture, Sports, Science and Technology, Japan for
SCADS inhibitor kit. This work was funded by a Grant-in-Aid for
3890 K. Hatsugai et al. / FEBS Letters 584 (2010) 3885–3890Scientiﬁc Research from the Ministry of Education, Culture, Sports,
Science and Technology, Japan.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2010.07.062.References
[1] Smith, S., Giriat, I., Schmitt, A. and de Lange, T. (1998) Tankyrase, a poly(ADP-
ribose) polymerase at human telomeres. Science 282, 1484–1487.
[2] Smith, S. and de Lange, T. (2000) Tankyrase promotes telomere elongation in
human cells. Curr. Biol. 10, 1299–1302.
[3] Seimiya, H., Muramatsu, Y., Ohishi, T. and Tsuruo, T. (2005) Tankyrase 1 as a
target for telomere-directed molecular cancer therapeutics. Cancer Cell 7, 25–
37.
[4] Seimiya, H. (2006) The telomeric PARP, tankyrases, as targets for cancer
therapy. Br. J. Cancer 94, 341–345.
[5] Seimiya, H. and Smith, S. (2002) The telomeric poly(ADP-ribose) polymerase,
tankyrase 1, contains multiple binding sites for telomeric repeat binding factor
1 (TRF1) and a novel acceptor, 182-kDa tankyrase-binding protein (TAB182). J.
Biol. Chem. 277, 14116–14126.
[6] Seimiya, H., Muramatsu, Y., Smith, S. and Tsuruo, T. (2004) Functional
subdomain in the ankyrin domain of tankyrase 1 required for poly(ADP-
ribosyl)ation of TRF1 and telomere elongation. Mol. Cell Biol. 24, 1944–1955.
[7] Sbodio, J.I., Lodish, H.F. and Chi, N.W. (2002) Tankyrase-2 oligomerizes with
tankyrase-1 and binds to both TRF1 (telomere-repeat-binding factor 1) and
IRAP (insulin-responsive aminopeptidase). Biochem. J. 361, 451–459.[8] De Rycker, M. and Price, C.M. (2004) Tankyrase polymerization is controlled by
its sterile alpha motif and poly(ADP-ribose) polymerase domains. Mol. Cell
Biol. 24, 9802–9812.
[9] Ohishi, T., Hirota, T., Tsuruo, T. and Seimiya, H. (2010) TRF1 mediates mitotic
abnormalities induced by Aurora-A overexpression. Cancer Res. 70, 2041–
2052.
[10] Ohishi, T., Tsuruo, T. and Seimiya, H. (2007) Evaluation of tankyrase inhibition
in whole cells. Methods Mol. Biol. 405, 133–146.
[11] Chang, W., Dynek, J.N. and Smith, S. (2003) TRF1 is degraded by ubiquitin-
mediated proteolysis after release from telomeres. Genes Dev. 17, 1328–1333.
[12] Kawada, M., Inoue, H., Masuda, T. and Ikeda, D. (2006) Insulin-like growth
factor I secreted from prostate stromal cells mediates tumor-stromal cell
interactions of prostate cancer. Cancer Res. 66, 4419–4425.
[13] Tanaka, J., Sadanari, H., Sato, H. and Fukuda, S. (1991) Sodium butyrate-
inducible replication of human cytomegalovirus in a human epithelial cell
line. Virology 185, 271–280.
[14] Gelmini, S., Poggesi, M., Distante, V., Bianchi, S., Simi, L., Luconi, M., et al.
(2004) Tankyrase, a positive regulator of telomere elongation, is over
expressed in human breast cancer. Cancer Lett. 216, 81–87.
[15] Xu, D., Zheng, C., Bergenbrant, S., Holm, G., Bjorkholm, M., Yi, Q., et al. (2001)
Telomerase activity in plasma cell dyscrasias. Br. J. Cancer 84, 621–625.
[16] McCabe, N., Cerone, M.A., Ohishi, T., Seimiya, H., Lord, C.J. and Ashworth, A.
(2009) Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated
cancer. Oncogene 28, 1465–1470.
[17] Huang, S.M., Mishina, Y.M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G.A.,
et al. (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt
signalling. Nature 461, 614–620.
[18] Zhou, H., Kuang, J., Zhong, L., Kuo, W.L., Gray, J.W., Sahin, A., et al. (1998)
Tumour ampliﬁed kinase STK15/BTAK induces centrosome ampliﬁcation,
aneuploidy and transformation. Nat. Genet. 20, 189–193.
[19] Yashiroda, Y., Okamoto, R., Hatsugai, K., Takemoto, Y., Goshima, N., Saito, T.,
et al. (2010) A novel yeast cell-based screen identiﬁes ﬂavone as a tankyrase
inhibitor. Biochem. Biophys. Res. Commun. 394, 569–573.
